PharmAla Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update
March 08, 2024 16:15 ET
|
PharmAla Biotech
PharmAla provides corporate update following AGM
FCM Plans for MM-120 (LSD) FDA Approval in 2026 And Extends Share Lockup Until June 15, 2026
June 07, 2023 08:07 ET
|
Concerned Shareholders of Company MindMed
FCM Confident in Ability to Start MM-120 Phase III in 2023 and Obtain FDA Approval In 2026 Dr. Freeman and Other FCM Directors Pledge to Extend Lockup Period For Selling Shares Until June 15, 2026 ...
ISS Appears to Rely on MindMed's False and Misleading Statements to Justify the Company's Abysmal Performance; Seemingly Ignores MindMed's Apparent Disregard of Patient Safety
June 05, 2023 06:19 ET
|
Concerned Shareholders of Company MindMed
ISS Dismissed 47% Stock Price Drop Following September 2022 Financing as In Line with “Sectoral Trends”, in a Baffling Lack of Critical Analysis and Seemingly in Opposition to the Factual...
World Renowned International Psychedelics Experts Join Clarion Clinics Advisory Board
May 30, 2023 08:00 ET
|
Incannex Healthcare
Highlights: Three world-leading clinical psychedelics experts join Clarion Clinics Advisory Board.Dr. Bill Richards is among the world’s best known psychedelic researchers and practitioners. He has...
Does Microdosing Impact Meditation? New Study From Beckley Foundation and Quantified Citizen Investigates
September 15, 2022 13:15 ET
|
Quantified Citizen
VANCOUVER, British Columbia, Sept. 15, 2022 (GLOBE NEWSWIRE) -- The Microdosing and Meditation Study, led by Beckley Foundation in collaboration with Psychedelic Data Society and Quantified Citizen...
Enzyme Replacement Therapy Market Worth $15.18 Billion by 2028 at 6.8% CAGR Led by Hospitals Segment (49% Market Share in 2021) Global Analysis by The Insight Partners
July 22, 2022 07:35 ET
|
The Insight Partners
New York, July 22, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Enzyme Replacement Therapy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By...
Optimi Health Requests Approval To Manufacture MDMA, Other Synthetic Psychedelics
June 20, 2022 09:00 ET
|
Optimi Health Corp.
VANCOUVER, British Columbia, June 20, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural,...
Franciosi Consulting Reviewing the Use of Psilocybin for Treating Depression, Anxiety and Addiction
January 06, 2022 14:00 ET
|
Franciosi Consulting Ltd.
VANCOUVER, British Columbia, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Lui Franciosi has been reviewing the science and history of psychedelic drugs for treating depression, anxiety and addiction....
Optimi Health and Numinus Wellness Submit All-Natural Psilocybin Extract to Health Canada for Pre-Clinical Trial Application
May 11, 2021 09:00 ET
|
Optimi Health Corp.
VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional...
MagicMed Industries to Present at the Q1 Virtual Investor Summit
March 19, 2021 08:15 ET
|
MagicMed Industries Inc.
CALGARY, Alberta, March 19, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- MagicMed Industries Inc. ("MagicMed" or the "Company"), a biotechnology company focused on creating novel psychedelic...